xalkori 200 mg capsule rigide
pfizer ag - crizotinibum - capsule rigide - crizotinibum 200 mg, silica colloidalis anhydrica, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 0.84 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - onkologikum - synthetika
xalkori 250 mg capsule rigide
pfizer ag - crizotinibum - capsule rigide - crizotinibum 250 mg, silica colloidalis anhydrica, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 1.05 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, kalii hydroxidum, e 172 (nigrum), pro capsula. - onkologikum - synthetika
xalkori
pfizer europe ma eeig - crizotinib - carcinoma, polmone non a piccole cellule - agenti antineoplastici - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
lorviqua
pfizer europe ma eeig - lorlatinib - carcinoma, polmone non a piccole cellule - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
alecensa
roche registration gmbh - alectinib cloridrato - carcinoma, polmone non a piccole cellule - agenti antineoplastici - alecensa in monoterapia è indicato per il trattamento di prima linea di pazienti adulti con carcinoma polmonare non a piccole cellule (nsclc) avanzato anaplastico-linfoma chinasi (alk) -positivo. alecensa come monoterapia è indicato per il trattamento di pazienti adulti con alk‑positivo nsclc avanzato precedentemente trattati con crizotinib.
zykadia
novartis europharm limited - ceritinib - carcinoma, polmone non a piccole cellule - agenti antineoplastici - zykadia è indicato per il trattamento di pazienti adulti affetti da carcinoma polmonare non a piccole cellule (nsclc) avanzato con anaplastico, linfoma e chinasi (alk) precedentemente trattato con crizotinib.
alunbrig
takeda pharma a/s - brigatinib - carcinoma, polmone non a piccole cellule - agenti antineoplastici - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
glucophage
bruno farmaceutici s.p.a. - metformina - metformina
metforal
laboratori guidotti s.p.a. - metformina - metformina
glibomet
laboratori guidotti s.p.a. - metformina e sulfonamidi - metformina e sulfonamidi